Abbott Laboratories $ABT Shares Sold by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 85.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 12,136 shares of the healthcare product maker’s stock after selling 70,140 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Abbott Laboratories were worth $1,246,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the 4th quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $88.95 on Wednesday. The business’s 50-day moving average is $89.27 and its two-hundred day moving average is $102.61. The company has a market capitalization of $154.94 billion, a P/E ratio of 24.92, a P/E/G ratio of 1.59 and a beta of 0.61. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Analyst Ratings Changes

Several analysts have weighed in on ABT shares. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. BTIG Research restated a “buy” rating and issued a $131.00 price objective on shares of Abbott Laboratories in a research note on Monday, April 27th. Evercore dropped their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Jefferies Financial Group cut their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Oppenheimer reduced their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $117.61.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.